What does entelo do?
Entelo is a cloud-based human resources solution that offers predictive analytics and social media integration to help recruiting organizations find, qualify and engage with prospective hires. Entelo’s search engine feature allows users to identify prospective hires with desired skills.
How many employees does Entelo have?
Entelo has 64 employees. They have 12 sales reps that carry a quota They have an engineering team of 18. and a marketing team of 2.
Who owns hiring solved?
HiringSolved is a product that lives up to its name. Clients of Allegis Global Solutions, an Allegis Group company, use HiringSolved to decrease time-to-fill on open reqs by 19% while decreasing the required recruiting headcount needed to make those hires by 17%.
Is Entelo a public company?
Entelo, Inc. is a privately held technology company located in San Francisco, California.
What is LOXO?
Loxo is a best-in-class enterprise recruiting SaaS company specializing in AI and machine learning, combining an ATS and CRM, and includes email automation, SMS texting, VoIP calling, personal contact information and candidate sourcing automation all-in-one easy to use platform.
What does LOXO cost?
$119.00/month
Pricing for Loxo starts at $119.00/month/user.
What LOXO 292?
Selpercatinib (LOXO-292) is an oral and selective investigational new agent that is being evaluated for the treatment of patients with cancers that harbor alterations in the RET kinase in the LIBRETTO-001 trial (NCT03157128).
How much is LOXO monthly?
Pricing for Loxo starts at $119.00/month/user. Q: What pricing for support is available for Loxo? Loxo offers support included with purchase.
What does LOXO mean?
oblique
word-forming element meaning “oblique,” before vowels lox-, from Greek loxos “bent to the side, slanting, oblique,” figuratively “ambiguous,” a word of uncertain origin.
What is RET fusion?
RET fusions or rearrangements are somatic juxtapositions of 5′ sequences from other genes with 3′ RET sequences encoding tyrosine kinase. RET rearrangements occur in approximately 2.5-73% of sporadic PTC and 1-3% of NSCLC patients. The most common RET fusions are CDCC6-RET and NCOA4-RET in PTC and KIF5B-RET in NSCLC.
Who makes LOXO 292?
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers | Eli Lilly and Company.